Cooley is advising Auxogyn on its merger with Fertility Authority. The combined company will be the first to provide fertility patients with easy access under one roof to high-quality doctors, price transparency and financing, extraordinary clinical expertise and proprietary clinical solutions. The company's headquarters will be located in New York with operations in Menlo Park, California.
By leveraging Fertility Authority's online patient-matching platform, the combined entity will enable more consumers to become educated about the benefits of single embryo transfer and about Auxogyn's Eeva Test. The Eeva Test is a first-in-class, FDA-cleared, noninvasive prognostic test that uses time-lapse imaging and statistical modeling to assess consistently and objectively early embryo development milestones with minimal disturbance to the embryo during incubation. The proprietary automated Eeva Test helps IVF clinicians optimize their treatment for patients undergoing IVF procedures. Auxogyn received a CE mark for the Eeva Test in July 2012, and FDA clearance in June 2014.
The team advising Auxogyn includes partner and head of Cooley's medical device practice, Mark Weeks, partner Danielle Naftulin and associates Rose Standifer and Hannah Minkevitch.
